Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 64,995 bioRxiv papers from 288,040 authors.
Deficiency of nucleotide excision repair explains mutational signature observed in cancer
Joep de Ligt,
Jakob Skou Pedersen,
Ruben van Boxtel,
Posted 17 Nov 2017
bioRxiv DOI: 10.1101/221168
Posted 17 Nov 2017
Nucleotide excision repair (NER) is one of the main DNA repair pathways that protect cells against genomic damage. Deficiency in this pathway can contribute to the development of cancer and accelerate aging. In addition, NER-deficiency is an important determinant for cancer treatment outcome, as NER-deficient tumors are sensitive to cisplatin treatment. Non-silent mutations in the NER-gene ERCC2 were previously associated with a specific mutational footprint (Signature 5), potentially providing a functional readout for NER-deficiency. However, not all NER-deficient tumors are characterized by a high Signature 5 contribution, illustrating the importance to further characterize the mutational consequences of NER-deficiency. Here, we analyzed the somatic mutational profiles of adult stem cells (ASCs) from NER-deficient progeroid Ercc1-/Δ mice, using whole-genome sequencing analysis of clonally derived organoids. Our results indicate that NER-deficiency increases the point mutation load in liver, but not in small intestinal ASCs, which coincides with a tissue-specific aging-pathology observed in these mice. More specifically, this increase can be largely explained by Signature 8, a mutational footprint observed in human cancer with as yet unknown etiology. The genomic distribution of the acquired point mutations indicates that deficiency of global-genome NER (GG-NER), rather than transcription-coupled NER (TC-NER), is responsible for the accumulated mutations. We independently confirmed the link between Signature 8 and GG-NER-deficiency through mutational analysis of a human organoid culture that was deleted for XPC using CRISPR-Cas9 gene-editing. Elevated levels of Signature 8 may, therefore, serve as a novel biomarker for GG-NER-deficient tumors and could improve personalized cancer treatment strategies.
- Downloaded 989 times
- Download rankings, all-time:
- Site-wide: 7,519 out of 64,995
- In molecular biology: 232 out of 2,056
- Year to date:
- Site-wide: 7,262 out of 64,995
- Since beginning of last month:
- Site-wide: 21,341 out of 64,995
Downloads over time
Distribution of downloads per paper, site-wide
- Top preprints of 2018
- Paper search
- Author leaderboards
- Overall metrics
- The API
- Email newsletter
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!